

**PART II OF THE PROSPECTUS FOR THE PUBLIC OFFERING OF THE SHARES OF
TCHAIKAPHARMA HIGH QUALITY MEDICINES INC**

The Supplement to this Registration Document is drawn up pursuant to Art. 85, Para. 2 of the POSA and in compliance with Commission Delegated Regulation (EU) № 382/2014 from the 7th of March 2014 supplementing Directive 2003/71 / EC of the European Parliament and the Council in respect to the regulatory technical standards for publishing a Supplement to the Prospectus and it only contains information relating to the occurrence of a significant new factor in the information contained in the approved Prospectus for the public offering of shares from the capital increase of Tchaikapharma High-Quality Medicines Inc., which may affect the assessment of the securities offered. The ensuing new circumstance is the increase of the amount of the capital of Tchaikapharma High Quality Medicines Inc. by its own means through the capitalization of profits pursuant to Art. 192 in conjunction with Art. 197 of the Trade Act, as well as a change in the Company Regulations. The changes were made pursuant to the Resolution of the General Meeting of shareholders on the 20th of April 2015. It is in the interest of investors before making an investment decision to familiarize themselves with the full text of the Prospectus comprising the Registration Document, the Securities Offering Document and the Summary and with the Supplement to the Prospectus consisting of a Supplement to the Registration Document, the Supplement to the Securities Offerings Document and a Supplement to the Summary. The Prospectus contains the entire information which, according to the peculiarities of the company and the publicly offered securities, is required to make an investment decision, including the main risks related to the company and its activities. The Financial Supervision Commission has confirmed the Supplement to the Registration Document (as part of the Prospectus) with Resolution № 304 - ПД from the 21st of April 2015 and the Supplement to the Registration Document (as part of the Supplement to the Prospectus) with Resolution №/....., which is not a recommendation to invest in the offered securities. The Financial Supervision Commission is not responsible for the correctness and completeness of the information contained therein. The members of the Board of Directors of Tchaikapharma High Quality Medicines Inc. are jointly liable for the damages caused by false, misleading or incomplete data in the Supplement to the Registration Document. The legal representative of the issuer declares that, having taken all reasonable care, he is satisfied that such is the case, that the information contained in the Supplement to the Registration Document, to his best knowledge, is complete and correct, that it corresponds to the facts and contains no omission that is likely to affect its meaning and that the Supplement to the Registration Document complies with the requirements of the law. The draftsmen of the financial statements of the Company are jointly liable along with the persons referred to in the first sentence of Art. 81, Para. 3 of the POSA, for damages caused by false, misleading or incomplete data in the financial statements of the Company and the auditors - for damages caused by their audited financial statements.

TCHAIKAPHARMA HIGH QUALITY MEDICINES INC

Investors can obtain the Prospectus and the Supplement to the Prospectus to get acquainted with its contents in the office of Tchaikapharma High Quality Medicines Inc. at:

1172 Sofia, № 1GM Dimitrov Blvd., every working day from 08:30 to 17.30 o'clock
as well as at the Information Center of the Financial Supervision Commission at:

Sofia, № 16 Budapest Str., every working day from 9.00 to 17.00 o'clock.
PBX of the Commission: 02/94 04 999.

The telephone number of Tchaikapharma High Quality Medicines Inc. is: 02/9603 634, contact person: Biser Ivanov.

Tchaikapharma High Quality Medicines Inc. informs its potential investors that investing in the offered shares involves certain risks, which are discussed in detail in the Registration document, insofar as it contains information on the risks associated with the Issuer and his activities. Risks related to the securities offered are detailed in the Securities Offerings Document.

1. THE SUPPLEMENT TO THE REGISTRATION DOCUMENT IS TO UPDATE SECTION:

V. INFORMATION ABOUT THE ISSUER 1. History and Development "Tchaikapharma High Quality Medicines Inc., a) Significant events in the business development of the Company

THE CONTENT OF THE SECTION WILL APPEAR AS FOLLOWS:

Important events in the development of the Issuer for the last years:

- No transformations have taken place in Tchaikapharma High Quality Medicines Inc.
- There have been no transfers or liens of Tchaikapharma High Quality Medicines Inc.
- There have been significant changes in the scope of activity of Tchaikapharma High Quality Medicines Inc.
- There are no filed claims for insolvency proceedings against the Company
- Pursuant to the resolution of the General Meeting, listed as Resolution from the 26th of October 2005 under Company Case № 1096/2000 of the the Varna Regional Court, the capital was increased from BGN 500 000 to BGN 2 500 000, through the issuance of 2 000 000 ordinary shares. The capital was increased under Art. 197 of the Commerce Act, through the capitalization of the profits and the new shares were distributed among the shareholders in proportion to their participation in the capital before the increase.
- Pursuant to the resolution of the General Meeting, listed as Resolution from the 04th of May 2006 under Company Case № 1096/2000 of the Varna Regional Court, the capital was increased from BGN 2 500 000 to BGN 5 299 000, through the issuance of 2 799 000 ordinary shares. The capital was increased under Art. 197 of the Commerce Act, through the capitalization of the profits and the new shares were distributed among the shareholders in proportion to their participation in the capital before the increase.
- Pursuant to the resolution of the General Meeting from the 15th of October 2006 the type of shares changed and all shares of the Company were dematerialized.
- Pursuant to the resolution of the General Meeting from the 07th of April 2007, the capital was increased by BGN 5 299 000 to BGN 10 598 000 through the issuance of 5 299 000 new dematerialized ordinary shares with a nominal value of BGN 1 (one). The capital increase was performed through the capitalization of profits pursuant to Art. 197 of the Trade Law.
- By decision № 179-ПД of the Financial Supervision Commission from the 29th of January 2007 the Company was registered as public in the kept under Art. 30, Para. 1, Item 3 of the FSCA Registry for trading on the regulated market. By the same Decision the Commission approved the Prospectus for the secondary public offering of an issue of shares in the amount of BGN 5 299 000, divided into 5 299 000 ordinary, dematerialized shares, including entering the issued shares of Tchaikapharma High Quality Medicines Inc. into the FSC Register. By Decision № 1624-ПД from the 19th of December 2007 of the substituting Vice Chairman of the FSC, managing Investment Supervision, the aforementioned issue of securities as well as the public company was delisted from the Register under Art. 30, Para 1, Item 3 of the FSCA. The reason for this removal was the failure to register the shares to trading on the regulated market within three months, an imposed consequence of the global financial crisis in 2007. That reflected noticeably in Bulgaria, and in this regard the management of the Issuer decided not to offer public shares.

- Pursuant to the resolution of the General Meeting from the 17th of February 2008 the capital was increased from BGN 10 598 000 to BGN 17 726 000 by issuing 7 128 000 new dematerialized ordinary shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.
- Pursuant to the resolution of the General Meeting from the 19th of April 2008 the capital was increased from BGN 17 726 000 to BGN 18 431 540 through an in-kind contribution.
- Pursuant to the resolution of the General Meeting from the 21st of June 2009 the capital was increased from BGN 18 431 540 to BGN 24 435 022 by issuing 6 003 482 new dematerialized ordinary shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.
- Pursuant to the resolution of the General Meeting from the 15th of November 2010 the capital was increased from BGN 24 435 022 to BGN 31 795 022 by issuing 7 360 000 new dematerialized ordinary shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.
- Pursuant to the resolution of the General Meeting from the 11th of April 2011 the capital was increased from BGN 31 795 022 to BGN 32 000 000 by issuing 204 978 new dematerialized ordinary shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.
- Pursuant to the resolution of the General Meeting from the 26th of August 2014 the capital was increased from BGN 32 000 000 to BGN 43 500 000 by issuing 11 500 000 (eleven million five hundred thousand) new dematerialized ordinary shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.
- The actual size of the Company's capital is BGN 43 500 000, divided into 43,500,000 dematerialized ordinary shares with voting right, with a nominal value of BGN 1 (one) each.
- Pursuant to the resolution of the General Meeting from the 20th of April 2015 the capital was increased from BGN 43 500 000 to BGN 49 600 000 by issuing 6 100 000 (six million one hundred thousand) new dematerialized ordinary shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.
- The actual size of the Company's capital is BGN 49 600 000, divided into 49 600 000 dematerialized ordinary shares with voting right, with a nominal value of BGN 1 (one) each.

2. THE SUPPLEMENT TO THE REGISTRATION DOCUMENT IS TO UPDATE SECTION:

VII. ORGANIZATIONAL STRUCTURE 1. Description of the structure of the Issuer

THE CONTENT OF THE SECTION WILL APPEAR AS FOLLOWS:

TCHAIKAPHARMA HIGH QUALITY MEDICINES INC

Tchaikapharma High Quality Medicines Inc. has no subsidiaries and is not part of an economic group within the meaning of § 1, p. 7 of the Additional Provisions of Decree № 2 from the 17th of September 2003, according to which the group consists of a company parent and its subsidiaries.

Tihomir Kamenov Dimitrov holds directly 47 616 000 ordinary shares with voting rights, representing 96% of the capital and the votes at the General Meeting of the Issuer.

3. THE SUPPLEMENT TO THE REGISTRATION DOCUMENT IS TO UPDATE SECTION:

XVIII. MAJOR SHAREHOLDERS 1. Persons, other than the members of the management body, who directly or indirectly participate in the capital of the Issuer or the shares with voting rights, their participation having to be disclosed under Bulgarian law, together with the degree of participation of each person like that, 2. Voting rights, 3. Control

THE CONTENT OF THE SECTION WILL APPEAR AS FOLLOWS:

The designated in Bulgarian legislation threshold at which each shareholder is obliged to disclose information about his/her direct and/or indirect participation in the capital of a public company, as is Tchaikapharma High Quality Medicines Inc., is the attaining, exceeding or falling below 5 per cent or a number divisible by 5 per cent of the votes in the general meeting of a public company.

Tihomir Kamenov Dimitrov is a shareholder Tchaikapharma High Quality Medicines Inc., and owns directly 47,616,000 dematerialized shares, representing 96% of the capital and votes in the General Meeting.

The issuer is not aware of the existence of agreements on exercising voting rights on the issued shares.

The Company was formed with a capital of BGN 500 000. The main shareholder Tihomir Kamenov has held 96% of the capital and votes in the General Meeting, and Tony Vekov - the remaining 4% of the capital and votes in the General Meeting from the establishment of the Company to the present moment.

The main shareholders of the Issuer do not have different voting rights.

After the formation of the company the following changes occurred in the number of shares owned by the aforementioned persons as a result of capital increases by capitalization of profits under which the new shares were acquired by the shareholders in proportion to their share in the capital before the increase:

Pursuant to the resolution of the General Meeting, listed as Resolution № 7118 of 26th of October 2005, under company case № 1096/2000 of the Varna District Court, the nominal value per share was reduced and become one BGN and the capital was increased from BGN 500 000 to BGN 2 500 000, through the issuance of 2 000 000 ordinary registered shares with voting rights, with a nominal value of BGN 1 each. The capital increase was carried out by capitalization of profits pursuant to Art. 197 of the Commercial Code.

TCHAIKAPHARMA HIGH QUALITY MEDICINES INC

Pursuant to the resolution of the General Meeting from the 19th of April 2006, listed as Resolution № 3168 from the 04th of May 2006, under company case № 1096/2000 of the Varna District Court, the capital was increased from BGN 2 500 000 to BGN 5 299 000, by issuing 2 799 000 new ordinary registered shares with voting rights, with a nominal value of BGN 1 each. The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

Pursuant to the resolution of the General Meeting from the 15th of October of 2006 a change was made to the type of shares where all shares of the Company were dematerialized.

Pursuant to the resolution of the General Meeting from the 07th of April 2007 the capital was increased from BGN 5 299 000 to BGN 10 598 000 by issuing 5 299 000 new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

Pursuant to the resolution of the General Meeting from the 17th of February 2008 the capital was increased from BGN 10 598 000 to BGN 17 726 000 by issuing 7 128 000 new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

Pursuant to the resolution of the General Meeting from the 19th of April 2008 the capital was increased from BGN 17 726 000 to BGN 18 431 540 through an in-kind contribution.

Pursuant to the resolution of the General Meeting from the 21st of June 2009 the capital was increased from BGN 18 431 540 to BGN 24 435 022 by issuing 6 003 482 new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

Pursuant to the resolution of the General Meeting from the 15th of November 2010 the capital was increased from BGN 24 435 022 to BGN 31 795 022 by issuing 7 360 000 new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

Pursuant to the resolution of the General Meeting from the 11th of April 2011 the capital was increased from BGN 31 795 022 to BGN 32 000 000 by issuing 204 978 new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

Pursuant to the resolution of the General Meeting from the 26th of August 2014 the capital was increased from BGN 32 000 000 to BGN 43 500 000 by issuing 11 500 000 (eleven million five hundred thousand) new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

Pursuant to the resolution of the General Meeting from the 20th of April 2015 the capital was increased from BGN 43 500 000 to BGN 49 600 000 by issuing 6 100 000 (six million one hundred thousand) new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

TCHAIKAPHARMA HIGH QUALITY MEDICINES INC

The actual size of the Company's capital is BGN 49 600 000, divided into 49 600 000 dematerialized dematerialized ordinary shares with voting right, with a nominal value of BGN 1 (one) each.

2. Voting rights

All shares of Tchaikapharma High Quality Medicines Inc. have the same rights. The aforementioned majority shareholder does not have different rights from other shareholders of the Company.

3. Control

Pursuant to item 14 of § 1 of the Supplementary Provisions of the POSA "control" occurs when a person:

1. holds including through a subsidiary or pursuant to an agreement with another person over 50% of the votes at the general meeting of a company or other legal entity; or
2. can determine directly or indirectly more than half of the management members or supervisory body of a legal entity; or
3. can otherwise exercise a decisive influence on the decision-making in connection with the activities of the legal entity..

As of the date this Supplement was drafted, Tihomir Kamenov Dimitrov has been exercising control over Tchaikapharma High Quality Medicines Inc. within the meaning of §1, item 14 of the Supplementary Provisions of the POSA , as he has directly owned 47 616 000 ordinary shares, representing 96% of the capital and votes in the General Meeting and has been able to appoint more than half of the management body members and exercise influence on the decision-making in connection with the activities of the Issuer. There has been no control on the Issuer by other persons withing the meaning of item 14 of §1 of the Supplementary Provisions of the POSA.

According to item 18.3 requirement of the Regulation, the Issuer is to describe the nature of the measures that have been introduced to prevent the misuse of control. Measures in place to prevent the misuse of the described influence and control are provided by the POSA, and the applicant has to declare that he will strictly conform to them.

The POSA provides for a specific regime for carrying out certain transactions of the public company that could be perceived as a kind of legal measure to limit the impact of persons who would have held a position of control if and when any person or persons acquire a similar position in relation to Tchaikapharma High Quality Medicines Inc.

The persons who manage or represent a public company, including individuals - representatives of a legal person who is a member of a governing body of a public company may not engage in transactions as described in Article 114, Para. 1, Items 1 - 7 of the POSA without being expressly authorized by the General Meeting of the public company.

The transactions of the public company with the participation of stakeholders beyond those mentioned in Art. 114, Para. 1 of the POSA, are subject to prior approval by the governing body of a public company.

According to Art. 114a, Para. 4 of the POSA when involved in decision making under Art. 114, Para. 1 of the POSA the interested persons cannot exercise their voting rights.

The interested members of the governing body are not involved in decision making pursuant to Art. 114, Para. 2 and 3 of the POSA. Pursuant to Art. 114a, Para. 5 of the POSA, the transactions under Art. 114, para. 1 pt. 1 and par. 2 of the POSA, involving interested persons, can only be carried out at market price.

The assessment is done by the governing body, and in the cases of Art. 114, Para. 1, Art. 1 b of the POSA – by determined by the governing body independent experts with the appropriate qualifications and experience.

Interested persons are members of the management and supervisory bodies of a public company, people - representatives of legal entities, members of such bodies, its procurator, persons who directly and / or indirectly hold at least 25 percent of the votes at the general meeting of the company or control it, and during transactions of a subsidiary – the members of the management and supervisory bodies, individuals - representatives of legal entities, members of such bodies, its procurator, persons who directly and / or indirectly hold at least 25 per cent of votes at the general meeting of the company, other than the public company, as well as related persons when they:

1. are a party, its representative or intermediary in the transaction or carrying out transactions or actions to their benefit;
2. hold directly and / or indirectly at least 25 percent of the voting rights in the general meeting or control a legal person that is a party or intermediary in the transaction or in whose favor the transactions or actions are conducted;
3. The members of the management or supervisory bodies, representatives of legal entities, members of such bodies or procurators of a legal person under points 1 and 2 above.

4. THE SUPPLEMENT TO THE REGISTRATION DOCUMENT IS TO UPDATE SECTION:

XX. FINANCIAL INFORMATION CONCERNING THE ASSETS AND LIABILITIES OF THE ISSUER, ISSUER'S FINANCIAL POSITION, PROFITS AND LOSSES 9. Significant changes in the financial or trading position of the Issuer

THE CONTENT OF THE SECTION WILL APPEAR AS FOLLOWS:

Pursuant to the resolution of the General Meeting from the 20th of April 2015 the capital was increased from BGN 43 500 000 to BGN 49 600 000 by issuing 6 100 000 000 (six million one hundred thousand) new dematerialized ordinary shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

There have been no other significant changes in the financial or business condition of the Issuer after the publication date of the last financial statement.

5. THE SUPPLEMENT TO THE REGISTRATION DOCUMENT IS TO UPDATE SECTION:

XXI. ADDITIONAL INFORMATION 1. Share capital a) Size

THE CONTENT OF THE SECTION WILL APPEAR AS FOLLOWS:

At the date of preparation of this Supplement the share capital of Tchaikapharma High Quality Medicines Inc. amounted to BGN 49 600 000. Unless otherwise specified, the data below is current to the date of the Supplement to the Registration Document.

Current amount of the share (basic) capital.....	BGN 49 600 000
Nominal amount per share.....	BGN 1
Issued and fully paid shares.....	49 600 000
Shares outstanding.....	49 600 000
Shares outstanding as of the 31st of December 2014.....	43 500 000

At the date of this Supplement to the Registration Document the entire capital of the Company, totaling BGN 49 600 000, has been fully paid in cash at the establishment of the Company and by capitalization of the profits in the subsequent capital increases.

All issued shares are of the same class - ordinary registered shares, and give equal rights to shareholders. Each issued by the Company share entitles to one vote in the General Meeting, the right to dividend and liquidation share being in proportion to the nominal value of the share.

The shares of the Company as of the date the Registration Document was drafted had not been accepted for marketplace trading.

No person has options over the capital of Tchaikapharma High Quality Medicines Inc. There are no persons regarding whom a commitment has been made (conditional or unconditional) to have options issued in their favor.

Eleven capital increases have taken place after the Company was formed, in which the new shares have not been paid in cash by the shareholders, as the increase was effected pursuant to Art. 197 of the Commercial Code - by capitalization of profits, and one was through an in-kind contribution.

6. THE SUPPLEMENT TO THE REGISTRATION DOCUMENT IS TO UPDATE SECTION:

XXI. ADDITIONAL INFORMATION 1. Share capital, g) Chare capital history

THE CONTENT OF THE SECTION WILL APPEAR AS FOLLOWS:

The Company was established and registered in the month of March 2000 with the capital of BGN 500 000, divided into 500 ordinary registered shares with a nominal value of BGN 1000 each.

After the establishment of the Company the nominal value of the share has changed and the capital has increased 10 times as follows:

TCHAIKAPHARMA HIGH QUALITY MEDICINES INC

- Pursuant to the resolution of the General Meeting, listed as Resolution № 7118 of 26th of October 2005, under company case № 1096/2000 of the Varna District Court, the nominal value per share was reduced and become one BGN and the capital was increased from BGN 500 000 to BGN 2 500 000, through the issuance of 2 000 000 ordinary registered shares with voting rights, with a nominal value of BGN 1 each. The capital increase was carried out by capitalization of profits pursuant to Art. 197 of the Commercial Code.
- Pursuant to the resolution of the General Meeting from the 19th of April 2006, listed as Resolution № 3168 from the 04th of May 2006, under company case № 1096/2000 of the Varna District Court, the capital was increased from BGN 2 500 000 to BGN 5 299 000, by issuing 2 799 000 new ordinary registered shares with voting rights, with a nominal value of BGN 1 each. The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.
- Pursuant to the resolution of the General Meeting from the 15th of October of 2006 a change was made to the type of shares where all shares of the Company were dematerialized.
- Pursuant to the resolution of the General Meeting from the 7th of April 2007 the capital was increased from BGN 5 299 000 to BGN 10 598 000, by issuing 5 299 000 new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.
- Pursuant to the resolution of the General Meeting from the 17th of February 2008 the capital was increased from BGN 10 598 000 to BGN 17 726 000, by issuing 7 128 000 new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.
- Pursuant to the resolution of the General Meeting from the 19th of April 2008 the capital was increased from BGN 17 726 000 to BGN 18 431 540 through an in-kind contribution.
- Pursuant to the resolution of the General Meeting from the 21st of June 2009 the capital was increased from BGN 18 431 540 to BGN 24 435 022, by issuing 6 003 482 new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.
- Pursuant to the resolution of the General Meeting from the 15th of November 2010 the capital was increased from BGN 24 435 022 to BGN 31 795 022, by issuing 7 360 000 new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.
- Pursuant to the resolution of the General Meeting from the 11th of April 2011 the capital was increased from BGN 31 795 022 to BGN 32 000 000, by issuing 204 978 new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.
- Pursuant to the resolution of the General Meeting from the 26th of August 2014 the capital was increased from BGN 32 000 000 to BGN 43 500 000, by issuing 11 500 000 (eleven million five hundred thousand) new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.
- Pursuant to the resolution of the General Meeting from the 20th of April 2015 the capital was increased from BGN 43 500 000 to BGN 49 600 000, by issuing 6 100 000 (six million one hundred thousand) new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

7. THE SUPPLEMENT TO THE REGISTRATION DOCUMENT IS TO UPDATE SECTION:

XXI. MORE INFORMATION, 2. Memorandum and Articles of Association, h) Provisions in the statutes of the Issuer, which manage the changes in the Issuer's capital

THE CONTENT OF THE SECTION WILL APPEAR AS FOLLOWS:

The Memorandum of Association of High Quality Medicines Tchaikapharma Inc. does not contain provisions regarding the capital changes which would be more restrictive than the conditions laid down by law. The foreseen in the Memorandum of Association majority necessary for adopting decisions regarding capital reduction and increase is 2/3 of the shares represented, as is the required by law majority for the adoption of such decisions.

Pursuant to Art. 196 of the Commercial Code, by decision of the General Meeting held on the 20th of April 2015 and according to Art. 20, Para. 2 of the Memorandum of Association, the Board of Directors is empowered within five years of the listing of the amendment of the Statute in the Commercial Register of the Court to make resolutions of capital increase up to BGN 100 000 000 by issuing new shares. According to Art. 19, Para. 2 of the Statute, the Board of Directors is authorized within the period designated in the previous sentence to adopt decisions and issue of bonds (including convertible) up to a total of BGN 50 000 000 or its equivalent in another currency.

After becoming a public company in accordance with the mandatory provisions of Art. 112, Para. 1, second sentence of the POSA, the Board of Directors will not have the right to restrict or exclude shareholders' rights under Art. 194, Para. 1 of the Commerce Act.

Upon capital increase by issuing new shares each shareholder has the right to acquire part of the new shares in proportion to his share in the capital before the increase. After the acquisition by the Company of a public status within the meaning of the POSA, upon capital increase by issuing new shares rights will be issued under § 1, item 3 of the POSA, where each existing share will issue one right. The ratio between the issued rights and one new share will be determined in the resolution for capital increase.

Under the current Statute and the Commerce Act, the capital may be reduced by reducing the nominal value of the shares or through the cancellation of shares after their purchase by the Company. The capital of the Company may not be reduced by canceling shares as this was not provided for in the Statute (Art. 201, Para. 2 of the CA), and after acquiring the status of a public company this way of capital reduction will not be possible due to the explicit prohibition of Art. 111, para. 2 of the POSA.

After acquiring the status of a public company in cases of capital reduction by cancellation of shares following their repurchase by the Company, the latter will be able to acquire within one calendar year more than 3 per cent of its own shares with voting rights only under the terms and conditions of the tender offer pursuant to Art. 149b in conjunction with Art. 111, Para. 5 of the POSA.

TCHAIKAPHARMA HIGH QUALITY MEDICINES INC

INVESTORS CAN GET ACQUAINTED WITH THE ORIGINAL PROSPECTUS AND THE SUPPLEMENT TO THE PROSPECTUS WITH THE DOCUMENTS, TO WHICH THEY REFER, AS WELL AS TO OBTAIN FURTHER INFORMATION ON THE PROSPECTUS AND THE SUPPLEMENT TO THE PROSPECTUS IN THE OFFICE OF TCHAIKAPHARMA HIGH QUALITY MEDICINES INC:

Sofia, 1172
District Izgrev, No1 G.M.Dimitrov Blvd.
as well as on the website:
www.tchaikapharma.com

The Supplement to the Registration Document was drafted by:

Biser Georgiev [signature]

Dimitar Stoyanov [signature]

Biser Ivanov [signature]

The undersigned, as a person representing the Company, with his signature declares that the The Supplement to the Registration Document meets the requirements of the law.

Biser Georgiev
[signature]

CEO
of Tchaikapharma High Quality Medicines Inc.